Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Combination of Ibuprofen, Magnesium, and Ascorbic Acid for TMJD Pain
NCT02602483Phase 2Completed
- Sponsor
- Spherium Biomed
- Start
- Dec 2015
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibuprofen, magnesium and ascorbic acid in temporomandibular joint disorders (TMD) (4 arms), sponsored by Spherium Biomed. Primary endpoint: Pain level assessed by VAS at 7 days. Started Dec 2015; status: completed.
02
Drugs
ibuprofenmagnesiumascorbic acid
03
Conditions
temporomandibular joint disorders (TMD)
Beyond the preview
Go deeper on NCT02602483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02602483.